BioCryst Pharmaceuticals Files 8-K
Ticker: BCRX · Form: 8-K · Filed: Mar 11, 2025 · CIK: 882796
Sentiment: neutral
Topics: 8-k, regulatory-filing
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K, likely with news.
AI Summary
On March 10, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not covered by other standard 8-K categories. No specific financial figures or new agreements were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that BioCryst Pharmaceuticals has reported a material event to the SEC, which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: medium — An 8-K filing often contains material information that can affect a company's stock price, necessitating investor attention.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- March 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
FAQ
What is the specific nature of the 'Other Events' reported by BioCryst Pharmaceuticals on March 10, 2025?
The provided excerpt does not specify the nature of the 'Other Events'; it only indicates that this category was used for the filing.
What is BioCryst Pharmaceuticals, Inc.'s principal executive office address?
BioCryst Pharmaceuticals, Inc.'s principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 10, 2025.
What is BioCryst Pharmaceuticals, Inc.'s IRS Employer Identification Number?
BioCryst Pharmaceuticals, Inc.'s IRS Employer Identification Number is 62-1413174.
In which state was BioCryst Pharmaceuticals, Inc. incorporated?
BioCryst Pharmaceuticals, Inc. was incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).